Skip to Content
MilliporeSigma

Skip To

1097658

USP

Cefixime

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Cefixime trihydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
500 mg

Available to ship TODAYfromMILWAUKEE

$435.00

About This Item

Empirical Formula (Hill Notation):
C16H15N5O7S2 · 3H2O
CAS Number:
Molecular Weight:
507.50
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

$435.00


Available to ship TODAYDetails


Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

pharmaceutical primary standard

API family

cefixime

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.O.O.Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O

InChI

1S/C16H15N5O7S2.3H2O/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7;;;/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27);3*1H2/b20-9-;;;/t10-,14-;;;/m1.../s1

InChI key

IPYWNMVPZOAFOQ-NABDTECSSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cefixime USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Cefixime for Oral Suspension
  • Cefixime Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
CDS021590C06840001097636
manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

EDQM

manufacturer/tradename

USP

grade

pharmaceutical primary standard

grade

-

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

format

neat

format

-

format

neat

format

neat

API family

cefixime

API family

-

API family

cefixime

API family

cefepime


pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Resp. Sens. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Francisco Toval et al.
Infection and immunity, 82(11), 4631-4642 (2014-08-27)
Enterohemorrhagic Escherichia coli (EHEC), a subgroup of Shiga toxin (Stx)-producing E. coli (STEC), is a leading cause of diarrhea and hemolytic-uremic syndrome (HUS) in humans. However, urinary tract infections (UTIs) caused by this microorganism but not associated with diarrhea have
Ali A Dashti et al.
BMC microbiology, 14, 214-214 (2014-08-29)
Escherichia coli O25b-B2-ST131 are considered virulent extra-intestinal pathogens causing serious clinical complications such as urinary tract infection and bacteraemia. Our main objectives in this study were to characterise the multi-drug resistant (MDR) isolates of this lineage in Kuwait, and to
Michael D Huband et al.
Antimicrobial agents and chemotherapy, 59(1), 467-474 (2014-11-12)
AZD0914 is a new spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with potent in vitro antibacterial activity against key Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae), fastidious Gram-negative (Haemophilus influenzae and Neisseria gonorrhoeae), atypical (Legionella pneumophila), and



Questions

Reviews

No rating value

Active Filters